PRESS RELEASEMÉRIGNAC, FRANCE – 26 MAY 2025 COMBINED GENERAL MEETING OF 23 MAY 2025 The Combined General Meeting (ordinary and extraordinary) of Exosens shareholders (the ‘Company’) was held on Friday 23 May 2025, chaired by Mr Jean-Hubert Vial, Chairman of the Board of Directors. The meeting was attended by Mr Jérôme Cerisier, Chief Executive Officer, Ms Quynh-Boï Demey, Chief Financial Officer, Ms Bella Zisère, Human Resources Director, and the Company's Statutory Auditors. HLD Europe and Bpifrance Partic ...

PRESS RELEASEMÉRIGNAC, FRANCE – 30 APRIL 2025 EXOSENS ANNOUNCES THE AVAILABILITY OF DOCUMENTS AND INFORMATION RELATING TO THE COMBINED GENERAL MEETING OF 23 MAY 2025 Shareholders of Exosens (the ‘Company’) are invited to attend the Combined General Meeting (ordinary and extraordinary) to be held on Friday, 23 May 2025 at 10 a.m. at Apostrophe, 83 avenue Marceau, 75016 Paris, France. The meeting notice, including the agenda and the text of the proposed resolutions, was published in the Bulletin des Annonce ...

Group 1 - Exosens has filed its 2024 Universal Registration Document with the French Financial Markets Authority (AMF) on April 29, 2025, under number R.25-001 [1] - The 2024 Universal Registration Document includes the Group's annual financial report, management report, Board of Directors' report on corporate governance, and sustainability report [1] - The document is available for viewing on Exosens' website and the AMF website, with printed versions obtainable upon request from the company's registered office in Mérignac, France [2] Group 2 - Exosens is a high-tech company with over 85 years of experience in the innovation, development, manufacturing, and sale of high-end electro-optical technologies [3] - The company offers detection components and solutions, including travelling wave tubes, advanced cameras, neutron and gamma detectors, instrument detectors, and light intensifier tubes [3] - Exosens is recognized as a major innovator in optoelectronics, with production and R&D across 11 sites in Europe and North America, employing over 1,800 staff [3] - The company is listed on compartment A of the regulated market of Euronext Paris and is a member of the Euronext Tech Leaders segment, included in several indices such as SBF 120 and MSCI France Small Cap [3]

Core Insights - Exosens reported strong revenue growth in Q1 2025, achieving €104.9 million, a 21.1% increase compared to Q1 2024, driven by robust demand in Defense markets [7][8][10] - The company is on track to meet its 2025 guidance, expecting high-teens revenue growth and low twenties adjusted EBITDA growth [3][23] Financial Performance - Total revenue for Q1 2025 was €104.9 million, up €18.3 million from Q1 2024, with a like-for-like growth of 18.0% [6][7] - Amplification revenue reached €81.7 million, reflecting a significant growth of 29.1% year-over-year, primarily due to increased demand for night vision applications [9][10] - Detection & Imaging revenue slightly declined to €24.0 million, down 1.0% compared to Q1 2024, impacted by temporary challenges in the Telops segment [11][12] Margin Analysis - Adjusted gross margin increased by 28.1% to €52.6 million in Q1 2025, with a margin rate of 50.1%, up 270 basis points from the previous year [8][17] - The Amplification segment's adjusted gross margin grew by 39.5% to €40.8 million, with a margin rate of 49.9% [18] - Detection & Imaging segment's adjusted gross margin remained stable at €11.8 million, with a margin rate improvement to 49.3% [19] Market Dynamics - The demand for Exosens' products is bolstered by increasing geopolitical tensions and sustained investments from NATO and Tier-1 allies [4][10] - The company anticipates continued growth in its Defense-related activities, with expectations for the Detection & Imaging segment to recover and accelerate throughout 2025 [12][23] Strategic Developments - Exosens completed the acquisition of Noxant, enhancing its capabilities in high-performance cooled infrared imaging, particularly for Defense and Surveillance applications [13][14] - The integration of Noxant is underway, expected to be finalized by the end of June 2025 [14] Governance and Shareholder Updates - Bpifrance Investissement is proposed for appointment to the Board of Directors, following an increase in its stake to 7.2% of Exosens' share capital [20][21] - The company maintains a leverage ratio target of around 2x while pursuing its growth strategy [24]